Rege Nephro Co., Ltd.
Company Details
Status: Private
Employees: 1-10
Location:
46-29 Yoshidashimoadachi-cho, Sakyo-ku, Med-Pharm Collaboration bldg. Kyoto University, Kyoto, Kyoto 606-8501, JP
Type:
sample
Technology:
sample
sample
sample
sample
sample
About: Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019.
There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan.
However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Rege Nephro Co., Ltd. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.